Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants | ||
By: Nasdaq / GlobeNewswire - 14 Feb 2018 | Back to overview list |
|
FIT Biotech Oy Company release February 14, 2018 at 5:45 pm EET FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On December 22, 2017, the Board of Directors of FIT Biotech Oy decided to establish Convertible Note and Warrant Programmes in order to implement the Convertible Notes with Warrants Funding Programme of up to EUR 10,000,000 of the same date between the Company and Alpha Blue Ocean. The Extraordinary General meeting approved the financing Programme on February 6, 2018. The Company's Board of Directors decided on February 14, 2018 to draw down the second tranche of EUR 500,000 included in the Programme and to issue to ABO a total of 500 Convertible Notes EUR 100 per note and 125,000,000 Warrants, which entitle to subscribe for the Company's K shares in accordance with the Characteristics of the Warrants. FIT BIOTECH OY Board of Directors For further information: Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000 About FIT Biotech FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines. FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy. DISTRIBUTION: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |